The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy. Median overall survival (OS) with nal-IRI+5-FU/LV was 6.1 vs 4.2 months with 5-FU/LV alone (unstratified hazard ratio [HR] = 0.67, P = .012).
| INTRODUC TI ON
Pancreatic cancer continues to have a bleak prognosis, 1 with an estimated 4.6-months median overall survival (OS; all stages from diagnosis 2 ) and only limited improvement in 5-year and 1-year survival rates. The incidence of pancreatic cancer is projected to rise over the next 10-15 years, and it is predicted to become the second leading cause of cancer-related death in the USA by 2030. 3 According to 2018 GLOBOCAN estimates, the age-standardized incidence rate (ASR) for pancreatic cancer in Asia is 3.9/100 000 persons and that of death is 3.6, compared with 7.7 and 7.0 for the USA and Europe combined. 4 A recent study including 40 European countries reported estimated ASR of 11.5/100 000 for incidence and 10.9 for death. 5 Chemotherapy for metastatic pancreatic cancer is guided by patient performance status (PS). Accordingly, in patients with good PS, first-line chemotherapy of metastatic pancreatic adenocarcinoma (mPAC) usually comprises FOLFIRINOX (5-fluorouracil and leucovorin [5-FU/LV] + irinotecan + oxaliplatin) or gemcitabine in combination with nab-paclitaxel. 2, [6] [7] [8] [9] In those with worse PS, treatment may be limited to gemcitabine monotherapy, oral 5-FU agents such as S-1, infusional 5-FU or best supportive care. 2, 7, 8, 10 For patients with mPAC that progressed following gemcitabine-based therapy, combination treatment with liposomal irinotecan (nal-IRI) and 5-FU/ LV has recently been approved by regulatory agencies in numerous countries. These approvals followed positive results from the global phase 3 NAPOLI-1 trial (NCT01494506). 11 In the intention-to-treat (ITT) population, nal-IRI+5-FU/LV combination significantly increased median OS versus 5-FU/LV alone (6.1 vs 4.2 months; unstratified hazard ratio [HR] = 0.67, P = .012).
The new formulation of the topoisomerase I inhibitor nal-IRI comprises irinotecan sucrosofate salt encapsulated in pegylated liposomes.
The formulation protects the drug from premature conversion and activation in the liver. As a consequence, circulation in the plasma in patients is extended. [12] [13] [14] The higher vascular permeability of tumor tissues may promote diffusion of nal-IRI from the circulation, with subsequent tumor-associated macrophage uptake and activation of the drug leading to an increase in local SN-38 concentrations. 13, [15] [16] [17] Time over the exposure threshold of the tumors to the active irinotecan metabolite, SN-38, has also been shown to increase in preclinical tumor models, and in plasma compared with tumor tissue, thereby increasing preclinical activity at lower levels. [12] [13] [14] In NAPOLI-1, ethnic origin was included as one of the stratification criteria (Caucasian vs East Asian vs all others). 11 Asian patients furthermore represent a large and diverse population with possible differences in pancreatic cancer incidence, mortality, and treatment options among Asian countries as compared with data available for Western populations. 1, 4, 5, [18] [19] [20] [21] Regional differences in treatment outcomes have been observed in pancreatic cancer, and other diseases (eg, advanced gastric cancer). [22] [23] [24] Previous work has also indicated differences in drug metabolism affecting the plasma concentration of SN-38 and irinotecan after nal-IRI treatment between patients of East Asian ethnicity and Caucasian ethnicity. 14, 25 It was reported that Asian patients had a significantly higher mean maximum plasma concentration (C max ) of unencapsulated SN-38 and a lower C max of total irinotecan after dosing with nal-IRI compared with Caucasian patients, which was associated with increased grade 3 or 4 neutropenia and decreased grade 3 or 4 diarrhea in Asian versus Caucasian patients. 25 Therefore, we carried out a post-hoc subgroup analysis of the NAPOLI-1 study assessing the efficacy and safety of nal-IRI+5-FU/LV in Asian patients treated at Asian centers, the results of which are presented here.
| ME THODS

| Study overview
Methodology and design of the NAPOLI-1 study have been described in detail and published elsewhere. 11 In summary, NAPOLI-1 was a nal-IRI monotherapy (n = 50) numerically improved efficacy endpoints versus 5-FU/ LV (n = 48): median OS was 5.8 versus 4.3 months (HR = 0.83, P = .423) and median PFS was 2.8 versus 1.4 months (HR = 0.69, P = .155). Grade ≥3 neutropenia was reported more frequently with nal-IRI+5-FU/LV versus 5-FU/LV (54.5% vs 3.4%), and incidence of grade ≥3 diarrhea was comparable between the two arms (3.0% vs 6.9%). This subgroup analysis confirms nal-IRI+5-FU/LV as an efficacious treatment option that improves survival in Asian patients with mPDAC that progressed after gemcitabine-based therapy, with a safety profile agreeing with previous findings. The nal-IRI+5-FU/LV regimen should represent a new standard of care for these patients in Asia. (Clinicaltrials.gov: NCT01494506)
K E Y W O R D S
Asian subgroup, clinical trial, phase 3, liposomal irinotecan, metastatic pancreatic cancer, NAPOLI-1 global, randomized phase 3 trial evaluating the safety and efficacy of nal-IRI+5-FU/LV (80 mg/m 2 irinotecan hydrochloride trihydrate salt equivalent to 70 mg/m 2 irinotecan free base, followed by 400 mg/m 2 LV prior to 2400 mg/m 2 5-FU, every 2 weeks) in adult patients with mPAC that had progressed after gemcitabine-based therapy compared with 5-FU/LV alone (200 mg/m 2 LV before 2000 mg/m 2 5-FU weekly for the first 4 weeks of each 6-week chemotherapy cycle). A third arm comprised nal-IRI monotherapy (120 mg/m 2 irinotecan hydrochloride trihydrate salt, equivalent to 100 mg/m 2 irinotecan free base every 3 weeks). Although initially designed to compare nal-IRI monotherapy with 5-FU/LV alone, the NAPOLI-1 trial was amended to add the nal-IRI+5-FU/LV arm when safety data on the combination became available. 26 Patients were randomized 1:1:1. All patients received best supportive care according to local institutional standards as part of their participation in the study. Prophylactic use of granulocytecolony stimulating factor (G-CSF) was permitted only in patients who experienced ≥1 episode of grade 3/4 neutropenia or neutropenic fever while on study treatment, or with documented grade 3/4 neutropenia or neutropenic fever while receiving prior antineoplastic therapy.
Prior to randomization, patients were stratified by ethnic- 
| Inclusion and exclusion criteria
Adult patients (aged 18 years and older, and with KPS ≥70) with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) and documented metastatic disease were eligible for inclusion in this study. Measurable or non-measurable lesions were graded according to RECIST guidelines version 1.1. Patients must have experienced disease progression after previous gemcitabinebased therapy that had been given in a neoadjuvant, adjuvant (only if distant metastases occurred within 6 months of completing adjuvant therapy), locally advanced, or metastatic disease setting. Adequate renal and hepatic function was required (including normal serum total bilirubin and albumin levels ≥30 g/L), as well as a neutrophil count >1.5 × 10 9 cells/L. Patients with active central nervous system metastasis, clinically significant gastrointestinal disorders and severe arterial thromboembolic events <6 months before enrolment were excluded.
| Outcomes
Primary efficacy endpoint of NAPOLI-1 was OS, with secondary endpoints including progression-free survival (PFS), time to treatment failure (TTF), and overall response rate (ORR). Safety and tolerability of study regimens were also evaluated. 
| Statistical analyses
| RE SULTS
Of the 417 patients included in the NAOPLI-1 study, 132 patients en- This analysis focuses on comparison of the nal-IRI+5-FU/ LV combination with 5-FU/LV control (enrolled after the protocol amendment) in patients from the Asia region. In the NAPOLI-1 study, nal-IRI monotherapy showed clinical activity versus 5-FU/ LV: ORR was 6.0% versus 0.7% (P = .020), and median PFS was 2.7 versus 1.6 months (HR = 0.81, P = .100). Although median OS was 4.9 months with nal-IRI monotherapy versus 4.2 months with 5-FU/ LV (HR = 0.99; P = .942), this did not reach statistical significance. Therefore, data for nal-IRI monotherapy are included in the present analysis for completeness (Tables 1-5 and Figure 2 ).
| Patient baseline characteristics and demographics
Patient demographics and baseline clinical characteristics were generally balanced across the nal-IRI+5-FU/LV and 5-FU/LV treatment arms ( Table 1 ). Some differences between the Asia region compared with the overall ITT population became apparent: all patients treated at Asian centers were of Asian ethnicity compared with approximately one-third in the overall population. A higher proportion of Asian patients had a baseline KPS of 90-100 versus the overall population for nal-IRI+5-FU/LV and 5-FU/LV, respectively, and fewer Asian patients in the nal-IRI+5-FU/LV arm had stage IV disease at initial diagnosis compared to the overall population ( Table 1 ). In the nal-IRI+5-FU/LV and 5-FU/LV arms, fewer Asian patients had received ≥2 lines of prior metastatic therapy compared with the overall population. Correspondingly, the proportion of patients who received one line of prior metastatic therapy was increased among Asian patients ( Table 1) . Only a single Asian patient in the nal-IRI+5-FU/LV arm was homozygous for the UGT1A1*28 genotype (Table 1 ). Fewer Asian patients had previously received gemcitabine monotherapy, whereas gemcitabinecontaining combinations had been used more frequently compared with the overall population. A minority of Asian patients had previously received treatment containing non-liposomal irinotecan.
A greater proportion of patients in the present analysis received post-study anticancer therapy compared with the overall population, with fluorouracil-containing therapies being the most commonly used in both populations ( Table 1 ). Includes only patients with a measured CA19-9 level prior to treatment. In the overall intent-to-treat population, data were missing for three patients in the nal-IRI+5-FU/LV group and in five patients in Columns add up to ≥100% as some patients received more than one prior line of therapy or more than one post-study treatment anticancer therapy and may therefore be included in more than one category.
| Efficacy
| Overall survival
TA B L E 1 (Continued)
(0.2-0.5) with 5-FU/LV, whereas the 12-month OS rates in the two treatment arms were 25% (0.1-0.4) and 17% (0.0-0.4), respectively. with 5-FU/LV alone (unstratified HR = 0.69, P = .155) ( Figure 2D ).
| Progression-free survival
| Objective response rate
A partial response was observed in three patients with nal-IRI+5-FU/ LV and none in those treated with 5-FU/LV alone, with an ORR of 8.8%
and 0%, respectively (P = .114) ( 
| CA19-9 response
The proportion of patients who achieved a tumor marker response (≥50% decrease from abnormal baseline value) was comparable between the global ITT population and Asian patients ( Table 2 ). In the Asia patient population, 32.0% and 7.7% (P < .001) achieved a CA19-9 response compared with 28.9% and 8.6% (P < .001) in the overall ITT population (nal-IRI+5-FU/LV and 5-FU/LV groups, respectively). A CA19-9 response was observed in 29.3% and 11.1%
(P = .024) of Asian patients receiving nal-IRI monotherapy and 5-FU/ LV, which was comparable to these treatment groups in the overall ITT population (23.6% and 11.4%, P = .024).
| Time to treatment failure
Patients treated with nal-IRI+5-FU/LV had a longer median TTF 
| Treatment duration and dose intensity
Patients treated with nal-IRI+5-FU/LV received an increased median number of treatment cycles compared with those receiving 5-FU/LV (3.0 vs 1.0), reflecting findings of the primary analysis (Table 3 ). In the present analysis, a larger proportion of patients in the combination arm spent ≥12 and ≥18 weeks on treatment compared with the control arm, whereas a similar percentage of patients in both arms were treated for ≥6 weeks, with 66.7% in the combination arm and 69.0% in the control arm (Table 3) including the nal-IRI monotherapy arm, were generally similar to the overall safety population ( Table 3 ). We observed that mean relative dose intensities for nal-IRI and 5-FU were somewhat lower in Asian patients receiving nal-IRI+5-FU/LV compared with the overall safety population (74.9% and 75.5% vs 83.2% and 83.9%).
| Safety and tolerability
The Asia region combination safety population comprised 62 patients, of whom 33 received nal-IRI+5-FU/LV, and 29 received the 5-FU/LV combination control ( 
5-FU/LV n = 134
Patients with TEAE leading to any dose modification, n (%) Tumor-associated fever 0 2 (6.9) 0 2 (4. 
Overall, the safety findings for patients receiving nal-IRI+5-FU/ LV at Asian centers were comparable with those treated with nal-IRI+5-FU/LV in the overall safety population (Table 4 ). There was an increased incidence of grade ≥3 neutropenia (54.5% vs 27.4%) and decreased WBC count (21.2% vs 7.7%) compared with the overall nal-IRI+5-FU/LV safety population. Conversely, there was a decreased incidence of diarrhea (3.0% vs 12.8%) compared with the overall nal-IRI+5-FU/LV safety population. Neutropenia-related TEAE more frequently led to dose delays and dose reductions in Asian patients receiving nal-IRI+5-FU/LV versus those in the overall safety population, whereas the incidence of treatment discontinuation was similar ( Table 5 ). Two out of seven patients with the homozygous UGT1A1*28 genotype developed grade ≥3 neutropenia in the overall nal-IRI+5-FU/LV arm. One of the two patients was in the Asian subgroup. This patient received an initial dose of 60 mg/m 2 nal-IRI as recommended by the study protocol and developed treatment-related grade 3 neutropenia during the first two treatment cycles, but no diarrhea. The neutropenia was managed initially with interruption of treatment, followed by reduction of nal-IRI dose to 50 mg/m 2 at the third treatment cycle. Grade 3 neutropenia recurred and the dose of nal-IRI was further reduced to 40 mg/m 2 at the fourth treatment cycle. A total of seven treatment cycles were given before treatment discontinuation as a result of disease progression.
| D ISCUSS I ON
The global NAPOLI-1 study showed that nal-IRI in combination nal-IRI monotherapy also showed some signs of activity, although this did not translate into any significant OS benefits.
In general, with the exception of ORR, patients at Asian centers had better outcomes than ITT patients. The ORR among patients at h Causes of death: Septic shock on study day 11, n = 1.
i Causes of death: Disseminated intravascular coagulation and pulmonary embolism on study day 12 (n = 1), gastrointestinal syndrome on study day 30 (n = 1), septic shock on study day 101 (n = 1), and infectious colitis on study day 206 (n = 1). In a population PK study of nal-IRI, the incidence of grade 3-4 neutropenia and diarrhea was significantly associated with plasma C max of unencapsulated SN-38 (uSN-38) and total irinotecan (tIRI), respectively. 25 Interestingly, Asian patients were found to have significantly higher uSN-38 C max and lower tIRI levels than the Caucasian population. 25 Although the findings provide a PK-based explanation for the ethnic differences in the incidence of neutropenia and diarrhea following nal-IRI treatment, the underlying molecular mechanisms behind these differences remain unclear.
In a previous randomized study of nal-IRI versus irinotecan versus docetaxel in gastric cancer showed that, for patients treated with nal-IRI, grade 3-4 neutropenia occurred more frequently for patients heterozygous for UGT1A1*6 (40% [2/5] versus the wild type genotype (3% [1/30]; P = .022). 14, 28 As the UGT1A1*6 allele occurs more frequently in Asian versus Caucasian populations, 28 could the increased incidence of neutropenia among the Asian patients in the NAPOLI-1 study versus the overall population be influenced by the presence of the UGT1A1*6 genotype in the Asian population?
Unfortunately, this genotype was not investigated in the NAPOLI-1 study population so we cannot draw any conclusions regarding this.
In contrast, the UGT1A1*28 genotype was not a predictor for uSN-38 clearance in the population PK study. 25 The finding that the single Asian patient homozygous for UGT1A1*28 was one of only two This ethnicity-pharmacokinetic association and its implication for treatment toxicity has been described in patients receiving non-liposomal irinotecan, and it has been suggested that ethnicity may influence irinotecan payload release kinetics from nal-IRI liposomes and ultimately plasma irinotecan levels. 25, 29 However, we also note that a higher proportion of patients in the Asia re- 
